Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial.

A Kaplan–Meier survival analysis showed a trend toward poor OS (3-year OS of 65% vs. 74%, p = 0.07) and significantly poor EFS overall (3-year EFS of 43% vs. 54%, p = 0.03) in low-FOXO3 expressers compared to patients with a high FOXO3 expression ( Figure 4 B).

also in 53,322 other papers